

SCIENTIFIC LETTER

Adult-onset cerebral X-linked adrenoleukodystrophy presenting with frontal lobe syndrome caused by a de novo *ABCD1* gene mutation (c.1415_1416delAG, p.Gln472fs*83)



Adrenoleucodistrofia ligada al cromosoma X de inicio en la edad adulta, debutando con un síndrome del lóbulo frontal causado por una mutación *de novo* en el gen *ABCD1* (c.1415_1416delAG, p.Gln472fs*83)

R. Ghosh^{a,1}, M. León-Ruiz^{b,1}, A. Jana^c, S. Dubey^d, J. Benito-León^{e,f,g,h,*}

^a Department of General Medicine, Burdwan Medical College and Hospital, Burdwan, West Bengal, India

^b Section of Clinical Neurophysiology, Department of Neurology, La Paz University Hospital, Madrid, Spain

^c Department of Radiodiagnosis, Burdwan Medical College and Hospital, Burdwan, West Bengal, India

^d Department of Neuromedicine, Bangur Institute of Neurosciences, Kolkata, West Bengal, India

^e Department of Neurology, 12 de Octubre University Hospital, Madrid, Spain

^f Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain

^g Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

^h Department of Medicine, Faculty of Medicine, Complutense University, Madrid, Spain

Received 25 July 2024; accepted 27 July 2024

Available online 24 February 2025

X-linked adrenoleukodystrophy is an uncommon genetic disorder characterized by impaired peroxisomal very-long-chain fatty acids (VLCFAs) beta-oxidation.^{1–5} Mutations in the *ABCD1* gene on the X chromosome are responsible for X-linked adrenoleukodystrophy. These mutations lead to the absence or dysfunction of adrenoleukodystrophy protein (ALDP), a peroxisomal transmembrane protein. ALDP is essential for transporting VLCFA-CoA esters from the cytosol into the peroxisome. This process is crucial for the catabolism of VLCFAs, and its disruption results in the

accumulation of these fatty acids, contributing to the pathology of the disease.^{1–5}

We report a patient with adult-onset cerebral X-linked adrenoleukodystrophy who presented with frontal lobe syndrome caused by a *de novo* mutation (c.1415_1416delAG, p.Gln472fs*83) in the *ABCD1* gene representing a novel phenotypic and genotypic variant, respectively.

A 50-year-old male patient from rural India was referred to our clinic in an akinetic-rigid-mute state. He was well two years back. From then, their family members referred progressive behavioral abnormalities in the form of depressed mood, diminished interest in pleasurable activities, loss of volition and initiative, feelings of guilt and worthlessness, significant psychomotor retardation, severe lack of energy, several suicidal attempts, extreme rage, coprolalia,

* Corresponding author at: Department of Neurology, University Hospital "12 de Octubre", Madrid, Spain.

E-mail address: jbenito67@gmail.com (J. Benito-León).

¹ RG and ML-R had equal contributions and can be considered joint first authors.

inappropriate jocularity (Witzelsucht), insight impairment, confabulation, utilization behavior and environmental dependency, and perseveration suggestive of frontal lobe syndrome. This picture was associated with progressive stiffening of lower limbs, loss of dexterity and clumsiness of upper limbs, and strained speech. Rapid advanced abnormal emotional regulations disrupted social behavior, and personality changes occurred. He also had recurrent unprovoked falls for the last year due to an unsteady gait. For the previous three months, he became bedridden and needed assistance for every daily life activity. One of his younger brothers had died at 45 with a similar neurological illness, which was not documented.

A general examination revealed an emaciated, bedridden individual who required assistance for all sorts of daily life activities. He was pale, had features of chronic malnutrition, and there was uncontrolled emotional and sphincter regulation and overt excessive salivation.

On neurological examination, he was mute and had rigidity (inability to relax muscles) and velocity-dependent resistance during muscle tone assessment compatible with paratonia. There were profound global cognitive impairments, apathy, anarthria, pseudobulbar palsy, symmetrical spastic quadripareisis, exaggerated deep tendon reflexes, and bilateral extensor plantar responses.

A complete blood cell count revealed microcytic, hypochromic anemia and neutrophilic leukocytosis with a raised erythrocyte sedimentation rate. Renal function tests revealed low serum creatinine. There was mild hyponatremia, hypokalemia, and mild hypoalbuminemia. Liver, thyroid, and parathyroid function tests were within normal range, and so were glycemic indices. Serologies for HIV (1, 2), hepatitis B and C viruses, John Cunningham virus, and syphilis were negative. Electrocardiography and echocardiography were unremarkable. Contrast-enhanced computed tomography scans of the neck, thorax, and abdomen were unremarkable.

Brain magnetic resonance imaging showed bilaterally symmetrical hyperintense lesions across T1-weighted, T2-weighted fluid-attenuated inversion recovery, and T2-weighted sequences. These lesions exhibited strongly restricted diffusion on diffusion-weighted imaging and showed patchy contrast enhancement. Affected areas

included the subfrontal and periventricular white matter, corticospinal tracts, and cerebellar white matter. Additionally, there was noticeable atrophy of the midbrain, pons, medulla, and cervical spinal cord. These findings were suggestive of adult-onset leukodystrophy (Figure 1).

Due to limited resources at our hospital for measuring plasma concentrations of VLCFAs, whole exome sequencing was initiated. This analysis revealed a hemizygous frame-shift mutation representing a novel pathogenic variant in the *ABCD1* gene. Precisely, the variant c.1415_1416delAG in exon 5 leads to a frameshift and premature protein truncation at amino acid 472 (p.Gln472fs*83). This mutation is associated with X-linked adrenoleukodystrophy, which explains the clinical presentation observed.

We also evaluated for associated adrenal insufficiency, which was ruled out. Genetic counseling was provided to caregivers and family members, during which the prognosis and implications of the genetic findings were thoroughly discussed.

Only one previously reported possible adult-onset X-linked cerebral adrenoleukodystrophy adult-onset case with frontal lobe dementia has been reported.⁶ Still, neither genetic testing nor whole exome sequencing was performed, and therefore, X-linked adrenoleukodystrophy diagnosis could not be confirmed.⁶ So, as far as we know, this would be the first reported confirmed X-linked adrenoleukodystrophy case with frontal lobe syndrome as presenting manifestation, originated by a de novo *ABCD1* gene mutation (c.1415_1416delAG, p.Gln472fs*83), which would constitute a novel phenotypic and genotypic variant, respectively.

It is essential to identify affected individuals with leukodystrophies promptly. However, there is a lack of awareness of these disorders, especially by nonspecific symptom presentation (e.g., cognitive or motor developmental delay), and X-linked adrenoleukodystrophy is among these disorders.⁷

In adults, early cognitive decline is rarely recognized by their families and friends or at work.⁵ As the disease progresses, psychiatric disturbances mimicking schizophrenia or psychosis are not infrequent.⁵ In those cases, X-linked adrenoleukodystrophy diagnosis is often delayed, mainly when no family history of X-linked adrenoleukodystrophy is




Figure 1 Magnetic resonance imaging of the brain reveals bilaterally symmetrical hyperintensity lesions on T1-weighted (A), T2-weighted-fluid-attenuated inversion recovery (B), T2-weighted images (C) with areas of strongly restricted diffusion on diffusion-weighted image, which was confirmed on the apparent diffusion coefficient map (not shown) (D) involving sub frontal periventricular white matter, the corticospinal tracts and cerebellar white matter, and atrophy of midbrain, pons, and medulla suggestive of adult-onset leukodystrophy.

present and when clinical symptoms of Addison's disease are absent (as in our case).⁵

It is important to note that in our case, the brain lesions exhibited significant diffusion restriction, indicative of demyelination and cellular damage within the white matter. Such imaging characteristics are commonly observed in toxic and metabolic leukoencephalopathies. This imaging pattern is somewhat atypical for leukodystrophies, which generally present with different MRI features. This finding underscores the complexity of diagnosing and distinguishing between various types of white matter diseases.⁸ Peripheral diffusion-weighted imaging hyperintensities and gadolinium enhancement are observable features in X-linked adrenoleukodystrophy;^{9,10} however, significant diffusion restriction should not rule out that entity.

Our case highlights the importance of (1) knowledge regarding phenotypic and genotypic X-linked adrenoleukodystrophy heterogeneity; (2) X-linked adrenoleukodystrophy may present as a frontal lobe syndrome in adulthood; (3) carefully understanding/interpreting neuroimaging characteristics of adult white matter disease patterns; and (4) asking for whole exome sequencing in case of a strong clinical suspicion of X-linked adrenoleukodystrophy for diagnostic confirmation.

Early recognition of frontal lobe syndrome heralding X-linked adrenoleukodystrophy could help achieve a prompt diagnosis, proper supportive management, and genetic counseling. Finally, further prospective and more extensive studies analyzing symptoms and prognosis associated with this novel *ABCD1* gene mutation, including frontal lobe syndrome as a phenotypic marker, are warranted.

Ethics approval and consent to participate

This case report involves a study with human data. The study was conducted respecting the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Formal ethics approval was waived. No reference number was provided, as approval was not required. Informed consent for participation in the study was obtained from the patient. The patient's identity has been protected, and all data presented are anonymized to maintain confidentiality.

Informed consent

Written informed consent was obtained from the patient participating in the study.

Study funding

No specific funding was received for this work.

Conflict of interest

Dr. Ritwik Ghosh (ritwikmed2014@gmail.com) reports no relevant disclosures.

Dr. Moisés León-Ruiz (pistolpete271285@hotmail.com) reports no relevant disclosures.

Dr. Arijeeet Jana (arijeet.jana.009@gmail.com) reports no relevant disclosures.

Dr. Souvik Dubey (drsovuk79@gmail.com) reports no relevant disclosures.

Dr. Julián Benito-León (jbenitol67@gmail.com) reports no relevant disclosures.

Acknowledgments

Julián Benito-León is supported by the National Institutes of Health (NINDS #R01 NS39422 and R01 NS094607) and the Recovery, Transformation, and Resilience Plan of the Spanish Ministry of Science and Innovation (grant TED2021-130174B-C33 and NETremor and grant PID2022-138585OB-C33, Resonate).

References

1. Ho JK, Moser H, Kishimoto Y, Hamilton JA. Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy. *J Clin Invest.* 1995;96:1455–63. <https://doi.org/10.1172/JCI118182>.
2. Singh I, Moser HW, Moser AB, Kishimoto Y. Adrenoleukodystrophy: impaired oxidation of long chain fatty acids in cultured skin fibroblasts an adrenal cortex. *Biochem Biophys Res Commun.* 1981;102:1223–9. [https://doi.org/10.1016/s0006-291x\(81\)80142-8](https://doi.org/10.1016/s0006-291x(81)80142-8).
3. Igarashi M, Schaumburg HH, Powers J, Kishimoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. *J Neurochem.* 1976;26:851–60. <https://doi.org/10.1111/j.1471-4159.1976.tb04462.x>.
4. Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. *Orphanet J Rare Dis.* 2012;7:51. <https://doi.org/10.1186/1750-1172-7-51>.
5. Rosebush PI, Garside S, Levinson AJ, Mazurek MF. The neuropsychiatry of adult-onset adrenoleukodystrophy. *J Neuropsychiatry Clin Neurosci.* 1999;11:315–27. <https://doi.org/10.1176/jnp.11.3.315>.
6. Shamim D, Alleyne K. X-linked adult-onset adrenoleukodystrophy: psychiatric and neurological manifestations. *SAGE Open Med Case Rep.* 2017;5, 2050313X17741009. <https://doi.org/10.1177/2050313X17741009>.
7. Garside S, Rosebush PI, Levinson AJ, Mazurek MF. Late-onset adrenoleukodystrophy associated with long-standing psychiatric symptoms. *J Clin Psychiatry.* 1999;60:460–8. <https://doi.org/10.4088/jcp.v60n0708>.
8. Modesti NB, Evans SH, Jaffe N, Vanderver A, Gavazzi F. Early recognition of patients with leukodystrophies. *Curr Probl Pediatr Adolesc Health Care.* 2022;52:101311. <https://doi.org/10.1016/j.cppeds.2022.101311>.
9. de Oliveira AM, Paulino MV, Vieira APF, McKinney AM, da Rocha AJ, Dos Santos GT, et al. Imaging patterns of toxic and metabolic brain disorders. *Radiographics.* 2019;39(6):1672–95. <https://doi.org/10.1148/rg.2019190016>. PMID: 31589567.
10. Mao C, Li J, Huang X, Wang J, Chu S, Zhang Y, et al. Typical and atypical phenotype and neuroimaging of X-linked adrenoleukodystrophy in a Chinese cohort. *Neurol Sci.* 2022;43(5):3255–63. <https://doi.org/10.1007/s10072-021-05859-y>. Epub 2022 Jan 8. PMID: 34997422.